| Ticker: | ACAD |
| Current Price: | $18.75 |
| % Daily Change: | 3.36% |
| Volume (1,000s): | 1,784.88 |
| Average Volume (1,000s): | 1,618.58 |
| Market Cap (M): | $3,240.54 |
| 1/2/2024 Price: | $30.86 |
| Change Since Inception: | -39.24% |
ACADIA Pharmaceuticals Inc.
12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.